Literature DB >> 22858560

Evaluation of different moxibustion doses for lumbar disc herniation: multicentre randomised controlled trial of heat-sensitive moxibustion therapy.

Mingren Chen1, Rixin Chen, Jun Xiong, Zhenhai Chi, Jianhua Sun, Tongsheng Su, Meiqi Zhou, Fan Yi, Bo Zhang.   

Abstract

BACKGROUND: There is some evidence for the effectiveness of moxibustion for the treatment of lumbar disc herniation (LDH), but it remains unclear what dose is optimal.
OBJECTIVE: To compare the effectiveness of a new technique of individualised 'sensitivity elimination' dose versus a standardised 15 min dose in the treatment of LDH.
METHODS: This study was a multicentre (four centres in China), randomised, controlled trial with two parallel arms (group A, individualised sensitivity elimination dose; group B, standardised dose). The most heat-sensitised acupuncture point from the triangle bound by BL25 and GV2 was selected. Both groups received 18 sessions over 2 weeks. The outcome was evaluated by Modified Japanese Orthopaedic Association scale (M-JOA) score before and after treatment and at 6-month follow-up examination. All main analyses were by intention to treat.
RESULTS: A total of 96 patients were included. A significant difference of total M-JOA score was noted between the groups at weeks 1 and 2 (p<0.05). Significant differences were also evident during the follow-up period (p<0.01). The mean duration of moxibustion was 42.7±5.4 (range, 22-58) minutes in the experimental group.
CONCLUSIONS: The effectiveness of the individualised sensitivity elimination dose appears superior to the standardised dose in the treatment of LDH. Only 15 min moxibustion in the conventional dose group seemed insufficient to elicit the satisfactory clinical effects obtained by heat-sensitive moxibustion therapy. However, in view of some limitations of this study further research is necessary before this can be stated conclusively. TRIAL REGISTRATION: Controlled Clinical Trials: ChiCTR-TRC-09000602.

Entities:  

Mesh:

Year:  2012        PMID: 22858560     DOI: 10.1136/acupmed-2012-010142

Source DB:  PubMed          Journal:  Acupunct Med        ISSN: 0964-5284            Impact factor:   2.267


  7 in total

1.  Cortical activities of heat-sensitization responses in suspended moxibustion: an EEG source analysis with sLORETA.

Authors:  Juan Wang; Ming Yi; Chan Zhang; Zhijie Bian; You Wan; Rixin Chen; Xiaoli Li
Journal:  Cogn Neurodyn       Date:  2015-07-16       Impact factor: 5.082

2.  Effects of Suspended Moxibustion on Delayed Onset Muscle Soreness: A Randomized Controlled Double-Blind Pilot Study.

Authors:  Ding Meng; Dong Xiaosheng; Wang Xuhui; Wang Xu; Zhang Xijin
Journal:  J Sports Sci Med       Date:  2017-06-01       Impact factor: 2.988

3.  The Case for Moxibustion for Painful Syndromes: History, principles and rationale.

Authors:  Nigel C Dawes; Joyce K Anastasi
Journal:  Curr Res Compliment Altern Med       Date:  2022-02-23

4.  Korean Medicine Clinical Practice Guidelines for Lumbar Herniated Intervertebral Disc in Adults: Based on Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Authors:  Bonhyuk Goo; Min-Gi Jo; Eun-Jung Kim; Hyun-Jong Lee; Jae-Soo Kim; Dongwoo Nam; Jung Won Kang; Tae-Hun Kim; Yeon-Cheol Park; Yong-Hyeon Baek; Sang-Soo Nam; Myeong Soo Lee; Byung-Kwan Seo
Journal:  Healthcare (Basel)       Date:  2022-01-27

5.  Effect of Different Dosages of ST36 Indirect Moxibustion on the Skin Temperature of the Lower Legs and Feet.

Authors:  Hiroshi Kuge; Hidetoshi Mori; Tateyuki Morisawa; Kazuyo Hanyu; Junji Miyazaki; Mayumi Watanabe; Tim Hideaki Tanaka
Journal:  Medicines (Basel)       Date:  2018-06-15

6.  Moxibustion for primary dysmenorrhea: A protocol for evidence-based clinical practice guideline.

Authors:  Rongrong Nie; Shouqiang Huang; Weiye Liao; Zhiming Mao; Xianglin Li; Jun Xiong
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

7.  The Characterization of Deqi during Moxibustion in Stroke Rats.

Authors:  Zhimai Lv; Zhongyong Liu; Dandan Huang; Rixin Chen; Dingyi Xie
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-08       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.